We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
KYMR Stock Gains as KT-485 Starts Patient Dosing in HS Study
Read MoreHide Full Article
Key Takeaways
KYMR began patient dosing in a phase I KT-485 study involving healthy volunteers and HS patients.
Sanofi's collaboration triggered a $20 million milestone payment upon study initiation.
KT-485 showed stronger potency, improved selectivity and a better safety profile than prior candidate KT-474.
Shares of Kymera Therapeutics (KYMR - Free Report) rose 4% after the company announced the initiation of patient dosing in the first-in-human phase I study of KT-485 (SAR447971), an investigational oral IRAK4 protein degrader being developed in partnership with Sanofi (SNY - Free Report) .
The study is evaluating KT-485 in healthy adult volunteers and patients with hidradenitis suppurativa (HS), marking the program's transition into clinical development. This triggered a $20 million milestone payment from Sanofi to Kymera under the companies’ collaboration agreement. The study will assess the candidate’s safety, tolerability, pharmacokinetics and exploratory biomarkers through single-ascending-dose, multiple-ascending-dose and open-label multiple-dose cohorts.
Year to date, shares of KYMR have lost 1.1% compared with the industry’s 3.1% decline.
Image Source: Zacks Investment Research
Terms of the Sanofi Deal for KT-485
Under the collaboration agreement, SNY is responsible for development, regulatory and commercialization activities associated with KT-485, while Kymera remains eligible for up to $975 million in potential development, regulatory and commercial milestone payments. KYMR also retains the option to participate in future U.S. development and commercialization efforts, including a 50/50 profit-sharing arrangement in the United States and is eligible for tiered double-digit royalties on sales in international markets.
More on Kymera’s KT-485
KT-485 is a second-generation oral degrader designed to eliminate IRAK4, a key protein involved in inflammatory and immune signaling pathways. IRAK4 plays a central role in the myddosome complex, which transmits signals from IL-1 and toll-like receptors that drive inflammation. By degrading the entire IRAK4 protein, KT-485 has the potential to provide a broader anti-inflammatory effect than traditional inhibitors.
In preclinical studies, KT-485 demonstrated greater potency, improved selectivity and a more favorable safety profile than the earlier IRAK4 degrader candidate, KT-474. These results led Sanofi to prioritize KT-485 for clinical development and discontinue KT-474, a decision that triggered a $20 million milestone payment to Kymera in 2025.
Over the past 30 days, earnings per share estimates for Indivior Pharmaceuticals remained unchanged at $4.05 for 2026 and $4.27 for 2027. INDV shares have risen 6.6% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
Over the past 30 days, estimates for Liquidia’s 2026 earnings per share have increased to $2.97 from $1.94. Over the same period, EPS estimates for 2027 have risen to $4.81 from $3.79. LQDA shares have surged 85.6% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
KYMR Stock Gains as KT-485 Starts Patient Dosing in HS Study
Key Takeaways
Shares of Kymera Therapeutics (KYMR - Free Report) rose 4% after the company announced the initiation of patient dosing in the first-in-human phase I study of KT-485 (SAR447971), an investigational oral IRAK4 protein degrader being developed in partnership with Sanofi (SNY - Free Report) .
The study is evaluating KT-485 in healthy adult volunteers and patients with hidradenitis suppurativa (HS), marking the program's transition into clinical development. This triggered a $20 million milestone payment from Sanofi to Kymera under the companies’ collaboration agreement. The study will assess the candidate’s safety, tolerability, pharmacokinetics and exploratory biomarkers through single-ascending-dose, multiple-ascending-dose and open-label multiple-dose cohorts.
Year to date, shares of KYMR have lost 1.1% compared with the industry’s 3.1% decline.
Image Source: Zacks Investment Research
Terms of the Sanofi Deal for KT-485
Under the collaboration agreement, SNY is responsible for development, regulatory and commercialization activities associated with KT-485, while Kymera remains eligible for up to $975 million in potential development, regulatory and commercial milestone payments. KYMR also retains the option to participate in future U.S. development and commercialization efforts, including a 50/50 profit-sharing arrangement in the United States and is eligible for tiered double-digit royalties on sales in international markets.
More on Kymera’s KT-485
KT-485 is a second-generation oral degrader designed to eliminate IRAK4, a key protein involved in inflammatory and immune signaling pathways. IRAK4 plays a central role in the myddosome complex, which transmits signals from IL-1 and toll-like receptors that drive inflammation. By degrading the entire IRAK4 protein, KT-485 has the potential to provide a broader anti-inflammatory effect than traditional inhibitors.
In preclinical studies, KT-485 demonstrated greater potency, improved selectivity and a more favorable safety profile than the earlier IRAK4 degrader candidate, KT-474. These results led Sanofi to prioritize KT-485 for clinical development and discontinue KT-474, a decision that triggered a $20 million milestone payment to Kymera in 2025.
KYMR’s Zacks Rank & Stock to Consider
Kymera currently carries a Zacks Rank #3 (Hold).
Two better-ranked stocks in the biotech sector are Indivior Pharmaceuticals (INDV - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 30 days, earnings per share estimates for Indivior Pharmaceuticals remained unchanged at $4.05 for 2026 and $4.27 for 2027. INDV shares have risen 6.6% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
Over the past 30 days, estimates for Liquidia’s 2026 earnings per share have increased to $2.97 from $1.94. Over the same period, EPS estimates for 2027 have risen to $4.81 from $3.79. LQDA shares have surged 85.6% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.